slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,351-7,380
Pages 328
Rows per page 30
Slide function
7,351-7,380 of 9,820
08
The slide uses a '2x-3x' metric to justify the value of genetic support in drug discovery, citing Nelson et al. (2015) and King et al. (2019).23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Logic Chain1 hit
18
The table uses checkmarks and crosses to indicate the presence or absence of specific therapeutic attributes across four different drug programs.Absci | Investor Conference Presentation Deck | 22 slides · Absci
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
04
a.k.a. Brands | Investor Presentation Deck | 14 slidesa.k.a. Brands | Investor Presentation Deck | 14 slides · a.k.a. Brands
Pitch deck Investor relations Beat · Early Struggles1 hit
23
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
26
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Evidence & ProofLoop · David Goliath1 hit
42
The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
43
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
44
The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and measurable disease definitions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
45
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a Venn diagram-like visual in the top left corner to indicate the current section of the presentation.Kering | ESG Presentation Deck | 80 slides · Moelis & Company
Conference presentation Investor relations Beat · Transformation1 hit
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
07
Uses a contrast-pair framework to highlight competitive advantages.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · Business Model1 hit
15
The slide highlights Lionsgate's performance relative to major competitors like Warner Bros, Disney, and Universal.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
19
The chart compares historical M&A transaction multiples (LTM EBITDA) for various media companies, with SEAC (Lionsgate) shown as a benchmark.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
25
The chart highlights Lionsgate Studios as the final bar in green, suggesting a valuation gap relative to peers like Netflix and F1.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market1 hit
08
The table highlights clinical status, mechanism of action, efficacy, safety, and strategic differentiation.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
16
The table highlights DA-1726's dual agonist mechanism and potential for better tolerability compared to market leaders.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
18
The slide uses three charts: a bar chart for food intake and two line charts for body weight loss (BWL) in different mouse models.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
19
The slide highlights that DA-1726 achieves weight loss through mechanisms other than just food reduction, as evidenced by higher food intake compared to Tirzepatide.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
16
The charts are kinome dendrograms (KinomeScan style).Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · CompetitionLoop · Quick Win Big Bet1 hit
14
The slide uses a checkmark matrix to validate the strategic rationale for two specific M&A deals.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Golden Circle1 hit
11
The slide uses pie charts to represent the relative weight of categories within each brand's portfolio.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Need1 hit
39
The competitor is represented by the French flag icon.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit